Signed into law in 2016, the landmark 21st Century Cures Act is as complex as it is divisive. For some stakeholders, including patient groups and representatives of regulated industries, the Act represented a major leap forward in pharmaceutical innovation, human subjects protections, and numerous other provisions. For other observers, this legislation was characterized as a major rollback in important regulations, which would leave patients worse off and the payers holding the bag. The one element of the Act that was relatively uncontroversial covered a number of provisions related to addressing the opioid crisis.This was by design. Provisions related to this issue were not part of the original legislation and were added to win over additional members of Congress who needed to be brought along to support the legislation. Many of the statute's provisions were intertwined with the Comprehensive Addiction Recovery Act (“CARA”) passed previously, but that legislation was stripped of much of its funding for opioid crisis response.

中文翻译：

---

阿片类药物危机的 21 世纪治愈方法：承诺、影响和错失的机会

2016 年签署成为法律，地标 21英石世纪治愈法既复杂又分裂。对于包括患者团体和受监管行业代表在内的一些利益相关者而言，该法案代表了药物创新、人体受试者保护和许多其他条款的重大飞跃。对于其他观察家来说，这项立法被描述为重要法规的重大倒退，这将使患者的情况变得更糟，而付款人则拿着袋子。该法案中相对没有争议的一个要素涵盖了许多与解决阿片类药物危机有关的规定。这是设计使然。与此问题相关的规定不是原始立法的一部分，而是为了争取其他国会议员的支持而增加的。许多法规'